Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 19/20 | 0.64 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736375 | 0.84 | CCR4 (0.59) | CCR4PTGES2 | |
| SCHEMBL1731222 | 0.78 | CCR4 (1.00) | CCR4 | |
| SCHEMBL29369177 | 0.78 | CCR4 (1.00) | CCR4 | |
| SCHEMBL5748169 | 0.78 | CCR4 (0.61) | CCR4 | |
| SCHEMBL5957166 | 0.78 | CCR4 (0.64) | CCR4 | |
| SCHEMBL5748366 | 0.77 | CCR4 (0.65) | CCR4 | |
| SCHEMBL4684562 | 0.77 | CCR4 (0.58) | CCR4PTGES2 | |
| SCHEMBL5738008 | 0.76 | CCR4 (0.70) | CCR4 | |
| SCHEMBL4682187 | 0.76 | CCR4 (0.69) | CCR4 | |
| SCHEMBL1731557 | 0.75 | CCR4 (0.78) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189613-A1 | Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | claimed |
| EP-1633723-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004108690-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| US-20060189613-A1 | Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1633723-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108690-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189613-A1 | Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) | CCR4, CCR5, CCR2 | CCR4 1/4885PTGES2 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.